- Home
- ABEO vs RDIB Comparison
ABEO vs RDIB Comparison
Compare ABEO & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | RDIB |
|---|---|---|
| Founded | 1974 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 259.2M |
| IPO Year | 1980 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | RDIB |
|---|---|---|
| Price | $5.06 | $11.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 6.1K |
| Earning Date | 11-12-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | $400,000.00 | ★ $211,292,000.00 |
| Revenue This Year | N/A | $1.06 |
| Revenue Next Year | $1,590.36 | $10.97 |
| P/E Ratio | $4.17 | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $3.93 | $5.78 |
| 52 Week High | $7.54 | $14.95 |
Technical Indicators
Market Signals| Indicator | ABEO | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 48.10 |
| Support Level | $4.53 | $10.88 |
| Resistance Level | $5.61 | $12.35 |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 49.30 | 37.95 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.